<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586062</url>
  </required_header>
  <id_info>
    <org_study_id>SIEA-PLG</org_study_id>
    <nct_id>NCT04586062</nct_id>
  </id_info>
  <brief_title>Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population</brief_title>
  <official_title>Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kedrion S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kedrion S.p.A.</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen&#xD;
      Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous&#xD;
      conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or&#xD;
      until a new clinical trial is available and the patients in treatment under Expanded Access&#xD;
      are eligible to participate in the new trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Ligneous Conjunctivitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasminogen</intervention_name>
    <description>Human Plasminogen</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects diagnosed with LC associated with Type I plasminogen deficiency, confirmed by&#xD;
             laboratory documentation at screening visit, with or without ocular pseudomembranes.&#xD;
             The presence of membranes in different areas is not an exclusion criterion.&#xD;
&#xD;
          -  Subjects and their legally authorized representative, in the case of subjects &lt;18&#xD;
             years of age, should be informed of the nature of the treatment, agree to its&#xD;
             provision, sign and date the informed and data handling consent forms approved by the&#xD;
             IRB.&#xD;
&#xD;
          -  Subjects must be available for the duration of the treatment and agree to be compliant&#xD;
             with the protocol visit and follow-up schedule.&#xD;
&#xD;
          -  Subjects agree to keep the treating physician or specialist in charge informed about&#xD;
             any occurrence related to the treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any condition which, in the opinion of the treating physician or&#xD;
             specialist in charge might interfere with the treatment.&#xD;
&#xD;
          -  Females of childbearing potential who are either pregnant or not using an adequate&#xD;
             method of birth control (adequate is defined as hormonal contraceptive or partner&#xD;
             vasectomy for at least 3 months, condoms, intrauterine device [IUD], abstinence or&#xD;
             other prescribed birth control). Enrolled males must agree to utilize appropriate&#xD;
             contraceptive methods to prevent pregnancy in partners.&#xD;
&#xD;
          -  Females who are breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Anna Lotti Suffredini</last_name>
    <phone>00390583767324</phone>
    <email>a.lotti@kedrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Pino</last_name>
    <phone>00390583767310</phone>
    <email>l.pino@kedrion.com</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

